Teijin Pharma Limited

Kabushiki Kaisha Toshiba

Toshiba Visual Solutions Corporation

Hirotsugu Kato

Hiroshi H Eguchi

Akira Tanokura

Kenichiro Takagi

Naoko Namiki

Satoshi Yamamura

Hirofumi Higuchi

Kenta Hibiya

Daisuke Ishikawa

Masayo Ohori

Tomoyo Takeo

Yusuke Kanamaru

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.

Anti-IGF-I receptor humanized antibody

The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.

SPNS2 neutralizing antibody

The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.

Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies

Growing community of inventors

Tokyo, Japan

Hirotsugu Kato